| Somatic mutations affect key pathways in lung adenocarcinoma L Ding, G Getz, DA Wheeler, ER Mardis, MD McLellan, K Cibulskis, ... Nature 455 (7216), 1069-1075, 2008 | 3163 | 2008 |
| Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers H Shigematsu, L Lin, T Takahashi, M Nomura, M Suzuki, II Wistuba, ... Journal of the National Cancer Institute 97 (5), 339-346, 2005 | 2983 | 2005 |
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer DP Kelsen, R Ginsberg, TF Pajak, DG Sheahan, L Gunderson, J Mortimer, ... New England Journal of Medicine 339 (27), 1979-1984, 1998 | 1688 | 1998 |
| Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie, P Balter, HJM Groen, ... The lancet oncology 16 (6), 630-637, 2015 | 1673 | 2015 |
| BRAF and RAS mutations in human lung cancer and melanoma MS Brose, P Volpe, M Feldman, M Kumar, I Rishi, R Gerrero, E Einhorn, ... Cancer research 62 (23), 6997-7000, 2002 | 1505 | 2002 |
| A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer JA Roth, F Fossella, R Komaki, MB Ryan, JB Putnam Jr, JS Lee, ... JNCI: Journal of the National Cancer Institute 86 (9), 673-680, 1994 | 1440 | 1994 |
| Characterizing the cancer genome in lung adenocarcinoma BA Weir, MS Woo, G Getz, S Perner, L Ding, R Beroukhim, WM Lin, ... Nature 450 (7171), 893-898, 2007 | 1295 | 2007 |
| Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression LB Owen-Schaub, W Zhang, JC Cusack, LS Angelo, SM Santee, ... Molecular and cellular biology 15 (6), 3032-3040, 1995 | 1102 | 1995 |
| Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. JA Roth, D Nguyen, DD Lawrence, BL Kemp, CH Carrasco, DZ Ferson, ... Nature medicine 2 (9), 985-991, 1996 | 1031 | 1996 |
| Gene therapy for cancer: what have we done and where are we going? JA Roth, RJ Cristiano Journal of the National Cancer Institute 89 (1), 21-39, 1997 | 929 | 1997 |
| Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, ... Cancer cell 39 (3), 346-360. e7, 2021 | 721 | 2021 |
| Induction of Chemosensitivity in Human Lung Cancer Cells in Vivo by Adenovirus-mediated Transfer of the Wild-Type p53 Gene T Fujiwara, EA Grimm, T Mukhopadhyay, WW Zhang, LB Owen-Schaub, ... Cancer research 54 (9), 2287-2291, 1994 | 695 | 1994 |
| Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer SG Swisher, JA Roth, J Nemunaitis, DD Lawrence, BL Kemp, ... Journal of the National Cancer Institute 91 (9), 763-771, 1999 | 659 | 1999 |
| Focus on lung cancer JD Minna, JA Roth, AF Gazdar Cancer cell 1 (1), 49-52, 2002 | 650 | 2002 |
| Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal … DP Kelsen, KA Winter, LL Gunderson, J Mortimer, NC Estes, DG Haller, ... Journal of Clinical Oncology 25 (24), 3719-3725, 2007 | 634 | 2007 |
| Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung … JA Roth, EN Atkinson, F Fossella, R Komaki, MB Ryan, JB Putnam Jr, ... Lung cancer 21 (1), 1-6, 1998 | 606 | 1998 |
| LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON. 3. EVIDENCE THAT IL-2 IS SUFFICIENT FOR DIRECT ACTIVATION OF PERIPHERAL-BLOOD LYMPHOCYTES INTO LYMPHOKINE-ACTIVATED KILLER CELLS EA Grimm, RJ Robb, JA Roth, LM Neckers, LB Lachman, DJ Wilson, ... JOURNAL OF EXPERIMENTAL MEDICINE 158 (4), 1356-1361, 1983 | 548* | 1983 |
| Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation LR Chirieac, SG Swisher, JA Ajani, RR Komaki, AM Correa, JS Morris, ... Cancer 103 (7), 1347-1355, 2005 | 531 | 2005 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 530 | 2021 |
| Survival in early-stage non-small cell lung cancer JC Nesbitt, JB Putnam Jr, GL Walsh, JA Roth, CF Mountain The Annals of thoracic surgery 60 (2), 466-472, 1995 | 526 | 1995 |
